Kornimate/medical-research-clean huggingface dataset:
feasibility of imaging in the treatment of patients with advanced head and neck cancer

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to obtain preliminary information on the potential of 99m tc-ec-dg spect imaging to distinguish cancer from non cancer.


Eligibility criteria:
inclusion criteria: * treatment naive patients with histologically proven cancer of the head and neck * t4 primary tumor (all sites), n2 or n3 locoregional disease (all sites) * at least one measurable site of disease * at least 18 years of age * karnofsky performance status \> or = 70% or ecog \<2 * able to tolerate spect/ct imaging * adequate bone marrow function * adequate liver function * adequate renal function * written consent from patients * female patients of childbearing potential must have a negative pregnancy test within 0-7 days prior to the first spect study exclusion criteria: * diabetics with insulin dependence or blood sugar levels \>200 mg/dl prior to imaging * patient weight above the spect/ct table weight limit * pregnant and/or lactating female * unequivocal demonstration of metastatic disease * patients unwilling to or unable to comply with protocol
construction of computerized intraoperative keratometer and experimental study

Conditions: Corneal Astigmatism; Orientation

Summary: to construct a computerized intraoperative keratometer to analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery.

the study is designed to construct a computerized intraoperative keratometer to analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery.

Eligibility criteria:
inclusion criteria: * cornea astigmatism from -1.0 d to -4.0d; exclusion criteria: * any significant corneal disease * other eye diseases induces impaired vision ,such as retinal detachment,keratoconus,pterygium,glaucoma,choroidal detachment,vitreous hemorrhage,congenital cataract,lens dislocation,anterior uveitis ,pupil deformation and so on; * previous corneal or intraocular surgery; * refuse surgery;
enoxaparin in the prevention of placental insufficiency in pregnant women

Conditions: Placental Insufficiency; Enoxaparin

Summary: assessment of the effectiveness of enoxaparin, at a preventive dose, combined with aspirin treatment versus aspirin only treatment in reducing placental insufficiency in pregnant women.

randomized, prospective, monocentric, open-label comparative study with two parallel groups (enoxaparin, at a preventive dose, combined with aspirin versus aspirin alone), with the main objective being to evaluate the effectiveness of enoxaparin, at a preventive dose, in reducing placental insufficiency during pregnancy in pregnant women.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years and * age ≤ 45 years and * single and confirmed pregnancy and * intrauterine growth restriction (iugr) history with an estimated fetal weight (esw) \< 3rd percentile and / or * in utero fetal death (iufd) history \> 12 weeks of amenorrhea (wa) and / or * central retroplacental hematoma (rph) history \< 34 wa and / or * history of severe preeclampsia \< 34 wa and * informed consent, written and obtained exclusion criteria: * age \<18 years or * age \> 45 years or * multiple pregnancy or * pregnancy \> 7 wa or * positive immunological assessment or * known history of thromboembolic diseases, hemorrhagic diseases, systemic lupus erythematosus (sle), heparin-induced thrombocythemia (hit), suspicion of thrombophilia (burdened history) or an episode of deep vein thrombosis (dvt) or * anticoagulation required or * thrombocythaemia \< 100,000 plq / µl or * weight \> 100 kg or * osteoporosis or * known allergy to the study products or * inability to ensure injections' administration or * family history of dvt before 40 years of age or
the efficacy of repetitive transcranial magnetic stimulation in patients with chronic subjective tinnitus

Conditions: Tinnitus

Summary: the aim of this study is to compare the efficacy of frequency-specific patterned repetitive transcranial magnetic stimulation (rtms) and 1hz rtms for the treatment of chronic subjective tinnitus. in this single-blind randomized controlled study, patients will be randomly assigned 1:1 to receive two different types of rtms stimulation.

tinnitus is a common disorder with a prevalence of 10-25% among adults, which seriously affects the quality of life of patients. many studies have reported significant efficacy of repetitive transcranial magnetic stimulation (rtms) for tinnitus, but its optimal stimulation parameters are not clear. therefore, there is necessary to assess the clinical efficacy and mechanism of different types of rtms for the treatment of chronic subjective tinnitus through rigorously designed clinical studies. the study will assess the severity of tinnitus and the mood and sleep status of the patients through several scales and tinnitus psychoacoustic assessment before treatment, after treatment and at follow-up. the primary research hypothesis is that frequency-specific patterned rtms will be superior to 1hz rtms in reducing tinnitus-related distress.

Eligibility criteria:
inclusion criteria: 1. adults aged between 18 and 80 years old. 2. experiencing persistant subjective tinnitus for at least 3 months. 3. a score of 38 or more on thi. 4. 50 db hl or less on the average pure tone threshold (0.5, 1, 2khz) of the worse ear. 5. voluntarily participate in the study and sign the informed consent form. 6. have normal mental status and cognitive function, and be able to cooperate with the research process. exclusion criteria: 1. diagnosis of meniere's disease, conductive hearing loss or objective tinnitus. 2. history of epilepsy or stroke. 3. diagnosis of acoustic neuroma. 4. severe sensorineural hearing loss. 5. surgically or traumatically implanted ferromagnetic foreign bodies, including but not limited to pacemakers, neurostimulators, prosthetic metal heart valves, aneurysm clips (non-titanium alloy), intraocular metal foreign bodies, cochlear implants, metal prostheses, metal joints, fixed steel plates or steel pins. 6. patients with active metal foreign bodies (metal implants, dentures, contraceptive rings), insulin pumps, etc., who have been evaluated in detail and are at risk for rtms treatment. 7. patients taking vestibular sedatives, antipsychotics, anxiolytics, antiepileptics, and ototoxic drugs. 8. patients with a recent history of alcohol or drug abuse 9. bell's palsy 10. acute ear infection within the last 1 month 11. inability to cooperate or complete the study process 12. participation in another clinical trial within the last month. 13. have any condition that may affect compliance or safety 14. any other condition that, in the opinion of the investigator, makes enrollment in the study inappropriate.

Keywords: tinnitus repetitive transcranial magnetic stimulation
effectiveness of aurix therapy in pressure ulcers

Conditions: Pressure Ulcer

Summary: the aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, randomized trial in which pressure ulcers will be treated using aurix and standard care and compared 1:1 to patients receiving undefined usual and customary care.

pressure ulcers (pus) are a common problem in all patient care settings, especially long-term acute care facilities and nursing homes. aurix is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds. the results of aurix to date when used to treat pus have been promising. the aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, randomized trial in which pressure ulcers will be treated using aurix and standard of care to determine time to heal at 16 weeks. comparison will be made to patients receiving undefined usual and customary care in a 1:1 manner.

Eligibility criteria:
inclusion criteria: 1. medicare eligible 2. ≥18 years of age 3. ulcer of pressure/shear etiology (stage ii, iii, and iv, see appendix 9 for stage definitions) 4. the largest non-healing wound, if multiple wounds are present, or the single wound to be treated (index ulcer) that is located on the heel, ischium, sacrum, and trochanter 5. for subjects with potentially multiple eligible pus, the largest ulcer will be selected as the index ulcer for study. there must be at least 4 cm between the index ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure) 6. debrided ulcer size between 3 cm2 and 200 cm2 7. subject has received ucc care for ≥ 2 weeks at treating wound clinic 8. demonstrated adequate pressure relief regimen 9. duration ≥ 1 month at first visit 10. subject must be willing to comply with the protocol, which will be assessed by enrolling clinician. exclusion criteria: 1. subjects known to be sensitive to aurix components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin 2. stage i pressure ulcers 3. ulcers that are unstageable or of deep tissue morphology that have yet to become an open wound 4. presence of another wound that is concurrently treated and might interfere with treatment of index wound by aurix 5. ulcer not of pu pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, venous, or arterial etiology) 6. patients on chemotherapeutic agents or any malignancy in the wound area 7. subjects who are cognitively impaired 8. serum albumin of less than 2.5 g/dl 9. plasma platelet count of less than 100 x 109/l 10. hemoglobin of less than 10.5 g/dl 11. subject has inadequate venous access for repeated blood draw required for aurix administration. 12. life expectancy of \< 6 months.

Keywords: non healing wound
a study to investigate the safety, tolerability, and pharmacokinetics and pharmacodynamics following subcutaneous injections of pg-102 (mg12) in healthy adult and obesity participants.

Conditions: Healthy; Overweight

Summary: this is a phase 1, first-in-human (fih), randomized, double-blind, placebo-controlled, combined single (part a) multiple (part b, c) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and pharmacodynamics following subcutaneous injections of pg-102(mg12) in healthy adult participants. this study will be conducted in 3 parts (part a, b and c), with up to 5 cohorts in each part.

part a (sad): in part a, subjects will receive a single dose of study drug, and the safety and efficacy of pg-102(mg12) will be evaluated in healthy subjects. part b (mad): in part b, subjects will receive once-weekly doses of the study drug for 4 weeks, and the safety and efficacy of pg-102(mg12) will be evaluated in otherwise healthy overweight adult subjects. part c (mad): in part c, obese participants will receive five repeated subcutaneous doses of the study drug, and the safety and tolerability of pg-102 (mg12) will be assessed across two cohorts based on prior safety data from part b.

Eligibility criteria:
inclusion criteria: 1. male or female participants, aged 18 to 65 years inclusive at the time of signing informed consent 2. body mass index (bmi) of 18 to 30kg/m2 (inclusive) for part a, body mass index (bmi) of 25 to 30kg/m2 (inclusive) for part b and body mass index (bmi) 30 kg/m² or higher for part c \[exclusion criteria\] 1. history of administration of prescription drugs, herbal medicines, over-the-counter drugs, or vitamin supplements within 10 days prior to the study or history of the following drugs and/or other foods within 90 days prior to screening: * drugs that affect body weight (such as obesity medications, psychiatric drugs, beta blockers, diuretics, contraceptives, female hormones, proton-pump inhibitors (ppis), h2 receptor antagonists, health functional foods/supplements, and formulas designed for weight control). * drugs that have the potential to impact blood sugar, liver fat, and intestinal microorganisms (including glp-1 receptor agonists, dpp-4 inhibitors, sglt-2 inhibitors, thiazolidinediones (tzds), fish oil, polyunsaturated fatty acids (pufa), and ursodeoxycholic acid (udca)), as well as individuals who are currently using insulin. 2. history of gastrointestinal diseases (crohn's disease, ulcers, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of clinical trial drugs. 3. history of acute proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy. 4. history of surgical treatment for obesity within 2 years (example: bariatric surgery, gastric banding etc) or gastrointestinal procedures for weight loss (including lap-band®), or uncontrolled gastrointestinal disorders at screening (e.g., peptic ulcer, gastroesophageal reflux disease).
prospective observational study to predict severe oral mucositis associated with chemoradiotherapy in nasopharyngeal carcinoma based on deep learning

Conditions: Nasopharyngeal Carcinoma; Oral Mucositis

Summary: the goal of this observational study is to apply the cnn-based dl method to extract the three-dimensional spatial information of imrt dose distribution to predict the occurrence probability of serious radiotherapy and chemotherapy induced oral mucositis(srcom), and compare with a model based on dosimetry, ntcp or doseomics to improve the prediction accuracy of srcom, thus guiding the clinical planning design, reducing the occurrence probability of om, and may have the potential value of preventing serious complications and improving the quality of life in patients with nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * initial diagnosis, pathological histological diagnosis, the pathological type is non-keratotic carcinoma (according to the who pathological classification). * initial intensity-modulated radiotherapy (intensity modulated radiation therapy, imrt). * no previous radiotherapy was received. exclusion criteria: * patients with recurrent nasopharyngeal carcinoma. * radiotherapy plan cannot be obtained. * previous history of malignancy; previous radiotherapy. * the primary lesion and cervical metastatic lesions have received surgical treatment (except for diagnostic treatment).

Keywords: nasopharyngeal carcinoma oral mucositis deep learning
resistance characteristics and development of diagnostic model for postoperative uti in patients with kidney stones

Conditions: Urinary Tract Infection Complicated; Kidney Stones; Antimicrobial Resistance

Summary: the combined detection of hbp, adpn, ngal, and hs-crp enables the construction of a highly efficient diagnostic model, offering a novel strategy for early infection identification and risk stratification after surgery.

this study investigated pathogen distribution, antimicrobial resistance, and the diagnostic utility of biomarkers (hs-crp, hbp, ngal, adpn) for urinary tract infections (uti) after kidney stone surgery. a total of 130 patients with kidney stones, treated between february 2021 and december 2024, were included in this study. based on the occurrence of postoperative utis, they were categorized into the uti group (n=41) and the non-uti group (n=89). laboratory parameters, including wbc, nlr, neu, hs-crp, hbp, ngal, and adpn levels, were measured. midstream clean-catch urine samples from patients in the uti group were collected for pathogen identification and antimicrobial susceptibility testing. pearson correlation analysis was performed to assess the relationships among these biomarkers, roc curve analysis was conducted to evaluate diagnostic performance, and logistic regression analysis was used to identify independent risk factors for postoperative infections.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. diagnosis of urinary calculi confirmed by ct, x-ray, or ultrasound; 3. complete clinical data available. - exclusion criteria: 1. presence of active uti or other infections prior to surgery; 2. coexisting urological disorders (e.g., bladder cancer, neurogenic bladder); 3. prolonged use of immunosuppressants or antibiotics (\>2 weeks). -
muscle energy technique and mulligan's mobilization in breast cancer surgery patients

Conditions: Mobility Limitation; Muscle Relaxation; Kinematics; Postural; Defect; Breast Cancer

Summary: a recent study aimed to examine the combined effect of mulligan and muscle energy techniques on postural changes and shoulder kinematics among women who had undergone breast cancer surgery with axillary dissection.

90 female patients who had undergone breast cancer surgery with axillary dissection were recruited and randomly assigned to three groups. group a received mulligan and muscle energy technique, group b received mulligan technique only, and group c received muscle energy technique. the study measured shoulder kinematics and postural changes using a digital inclinometer for range of motion, pas/sapo for cervical angle, and the horizontal alignment of acromions and quick dash for upper extremity activities. outcome measurements were taken at three different time points: baseline, six weeks post-intervention, and eight weeks after the intervention during a follow-up assessment.

Eligibility criteria:
inclusion criteria: * female * between 50 and 65 years * limited shoulder range of motion exclusion criteria: * having metastases * lymphedema * traumatic or musculoskeletal disorders affecting the arm * not taking anticoagulants * not having undergone bilateral breast cancer surgery * not having a locoregional recurrence * not having vascular disorders in the affected arm
study to evaluate pf-04965842 in subjects with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: study b7451006 is a phase 2b poc study which is planned to assess four pf 04965842 once daily (qd) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of pf 04965842 in subjects with moderate to severe ad. the objectives of the study are to demonstrate the efficacy of pf 04965842 by showing improvement in disease severity in patients with moderate to severe ad as measured by the investigator's global assessment (iga) and eczema area and severity index (easi) scores, and safety to support further clinical development of pf 04965842.


Eligibility criteria:
inclusion criteria: * male or female subjects between 18 75 years of age, inclusive, at time of informed consent. * must have the following atopic dermatitis criteria: 1. have a clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year prior to day 1 and has confirmed atopic dermatitis (hanifin and rajka criteria of ad refer to appendix 2) at the screening visit. 2. have inadequate response to treatment with topical medications given for at least 4 weeks, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks) within 12 months of the first dose of study drug. 3. moderate to severe ad (affected bsa \>=10 %, iga \>=3, and easi \>=12 at the screening and baseline visits). exclusion criteria: * history of human immunodeficiency virus (hiv) or positive hiv serology at screening, * infected with hepatitis b or hepatitis c viruses. * have evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (tb) * have received any of the following treatment regiments specified in the timeframes outlined below: within 6 months of first dose of study drug: any cell depleting agents within 12 weeks of first dose of study drug: any studies with jak inhibitors; other biologics within 8 weeks of first dose of study drug: participation in other studies involving investigational drug(s) within 6 weeks of first dose of study drug: have been vaccinated with live or attenuated live vaccine. within 4 weeks of first dose of study drug: use of oral immune suppressants; phototherapy (nb uvb) or broad band phototherapy; regular use (more than 2 visits per week) of a tanning booth/parlor. within 1 week of first dose of study drug: topical treatments that could affect atopic dermatitis; herbal medications with unknown properties or known beneficial effects for ad.

Keywords: phase 2 randomized double-blind placebo atopic dermatitis safety efficacy jak janus kinase moderate severe
contrast ultrasound of the small intestine in patients with crohns disease

Conditions: Crohn Disease

Summary: the purpose of this study is to determine how relevant dynamic ultrasound scans using contrast agents (sonovue) is in the diagnosis of crohns disease in the small bowel, compared to dynamic magnetic resonance imaging (mri) of the small bowel.

crohns disease (cd) is a lifelong chronic inflammatory bowel disease (ibd) normally with an early debut. it requires continuous evaluation with either endoscopy, magnetic resonance imaging (mri), computed tomography (ct) or wireless capsule endoscopy (wce). these methods are either expensive, invasive or with uses radiation. therefore ultrasound (us), as a cheap, fast and well tolerated examination of the small bowel are tested against the the validated mri examination of the small bowel. both examinations are using intra venous (i.v.) contrast agents. obtained results are compared to disease activity. hypothesis is, that dynamic us is comparable to dynamic mri and therefore should be the first examination of choice in evaluating patients with cd. this study is a pilot study only.

Eligibility criteria:
inclusion criteria: * patients with known crohns disease * 18 years old or older. * referred to a magnetic resonance imaging scan of the small bowel exclusion criteria: * contraindications to or not suitable of a magnetic resonance imaging * liver transplant * nursing og pregnancy * known allergy of sonovue * acute myocardial infarction \< 4 weeks * coronary angiography \< 4 weeks * electrocardiogram changes \< 4 weeks * frequent and repetitive angina pectoris symptoms within the last week. * heartfailure * serious arrhythmia * right to left heart shunt * very high pulmonary artery pressure * uncontrolled hypertension * adult respiratory distress syndrome

Keywords: crohn disease ultrasonography, contrast enhanced elasticity imaging techniques small intestine magnetic resonance imaging cdai calprotectin ibd sonography